FEIBA


Also found in: Acronyms.

FEIBA

Factor VIII inhibitor–see there, or factor VIII bypassing activity. See Prothrombin complex concentrate.
References in periodicals archive ?
Results from the study demonstrated that routine prophylactic treatment with FEIBA NF reduced median annual bleed rate (ABR) from 28.
The prospective, open label, randomized, multi-center, parallel study investigated the efficacy, safety and health-related quality of life benefits of FEIBA NF prophylactic treatment compared to on-demand treatment in 36 patients with hemophilia A or B and inhibitors over a 12-month period.
FEIBA NF [Anti-Inhibitor Coagulant Complex] is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors.
may either be treated with Antihemophilic Factor or FEIBA NF.
The Phase III prospective, open label, randomized, multi-center, parallel study investigated the efficacy, safety and health-related quality of life benefits of FEIBA NF prophylactic treatment compared to on-demand treatment in 36 patients with hemophilia A or B and inhibitors over a 12-month period.
This latest study adds to the clinical evidence supporting the prophylactic use of FEIBA, building on an investigator initiated study showing that FEIBA can reduce bleeding events in patients with severe hemophilia A and inhibitors when compared to on-demand treatment (results published in The New England Journal of Medicine in November 2011).
The FEIBA NF prophylaxis study demonstrates Baxter's dedication to providing treatment options to the hemophilia community, including effective inhibitor management," said Prof.
The Prophylaxis with Factor Eight Inhibitor Bypassing Activity (Pro-FEIBA) study reported that patients with severe hemophilia A treated with FEIBA prophylactically during a six-month period experienced a 62 percent reduction in all bleeds in the prophylaxis period, an average of 5 bleeding events compared to an average of 13.
Of those patients in the study achieving a reduction in bleeds, all were achieved with three doses of FEIBA (85 U/kg O 15 percent) per week.
While joint and other bleeding episodes were reduced during the six-month prophylaxis period, a longer, larger, parallel design trial is needed to determine if regular FEIBA infusions are a safe and effective treatment option for hemophilia A patients with inhibitors.
1 - FEIBA NF 1000 IU powder for solution - 300 pcs- Task 2 - Advate 500 IU powder and solvent for solution - 550 pcs- Task 3 - Advate 1.
This performance was a result of robust growth across multiple products, including ADVATE(R) [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a therapy used in the treatment of hemophilia A, antibody therapy products for the treatment of primary immunodeficiencies, and other specialty plasma therapeutics such as FEIBA (an inhibitor therapy indicated for the control of spontaneous bleeding episodes in patients with hemophilia A and hemophilia B) and ARALAST (a human alpha-1 proteinase inhibitor (A1PI) for patients with hereditary emphysema).